TARS
Tarsus Pharmaceuticals IncNASDAQ
Healthcare • Biotechnology
Factor tilt: Mid-Cap Blend
$68.60+1.60%
Close Nov 6, 2026
- Market cap
- $2.95B
- 1 month
- -5.0%
- 3 months
- +1.2%
- 1 year
- +0.6%
- 52-week range
- $56.11$90.78
- Dividend
- No dividends on record
- Short interest
- 17.5% of float5.7M shares · settled Oct 15, 2026 · -5.6% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Sep 30, 2026
- Revenue
- $682.2M
- Net income
- -$702.23M
- Free cash flow
- $37.99M
- Book value
- $104.03M
- Total debt
- $88.67M
- P/E
- —
- Price / sales
- 4.3×
- Price / book
- 28.4×
- FCF yield
- +1.3%
- Net margin
- -102.9%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Read more
It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
- Website
- tarsusrx.com
- Headquarters
- Irvine, CA, United States
- Employees
- 370
- Listed
- Oct 16, 2020
- Fiscal year ends
- December
Company profile from EODHD, stored Nov 6, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Sep 2026filed Nov 3, 2026 | $194.6M | +63.9% | 92.9% | -$662.1M | -$668.3M |
| Jun 2026filed Aug 6, 2026 | $173.9M | +69.4% | 93.0% | -$19.9M | -$18.6M |
| Mar 2026filed May 6, 2026 | $162.1M | +106.9% | 94.2% | -$6.1M | -$7.0M |
| Dec 2025filed Feb 23, 2026 | $151.7M | +128.4% | 92.8% | -$8.0M | -$8.4M |
| Sep 2025filed Nov 4, 2025 | $118.7M | +146.7% | 79.3% | -$14.5M | -$12.6M |
| Jun 2025filed Aug 6, 2025 | $102.7M | +151.5% | 93.9% | -$22.2M | -$20.3M |
| Mar 2025filed May 1, 2025 | $78.3M | +183.7% | 93.3% | -$26.3M | -$25.1M |
| Dec 2024filed Feb 25, 2025 | $66.4M | +407.9% | 92.6% | -$24.4M | -$23.1M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 23, 2026 | $451.4M | +146.7% | 93.2% | -$71.0M | -$66.4M |
| Dec 2024filed Feb 25, 2025 | $183.0M | +948.6% | 93.0% | -$120.6M | -$115.6M |
| Dec 2023filed Feb 27, 2024 | $17.4M | -32.4% | 90.9% | -$143.2M | -$135.9M |
| Dec 2022filed Mar 17, 2023 | $25.8M | -54.7% | 96.3% | -$62.7M | -$62.1M |
| Dec 2021filed Mar 14, 2022 | $57.0M | +70.6% | 96.4% | -$12.2M | -$13.8M |
| Dec 2020filed Mar 31, 2021 | $33.4M | — | — | -$27.0M | -$26.8M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched TARS. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
5,731,409 shares short
-339,519 shares (-5.6%) vs Sep 30, 2026
17.5% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
6,070,928 shares short
-56,956 shares (-0.9%) vs Sep 15, 2026
18.5% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
6,127,884 shares short
+116,334 shares (+1.9%) vs Aug 31, 2026
19.1% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
6,011,550 shares short
+14,075 shares (+0.2%) vs Aug 14, 2026
18.7% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
5,997,475 shares short
-19,355 shares (-0.3%) vs Jul 31, 2026
18.7% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
6,016,830 shares short
+233,767 shares (+4%) vs Jul 15, 2026
18.7% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind TARS’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if TARS is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
45 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Sep 23, 2026
Smart-money 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bearish
Last trade: sell 51 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
257 filers reported a long position in TARS for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
52.3%
of the 47.3M shares 13-F filers reported
Moves vs Q1 2026
7 added2 trimmed
1 not comparable
Net shares held
+8.4%
across the 9 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | $242.7M · 3.9M shares | 3.9M | +8.5% |
| 2 | Deep Track Capital, LP | $230.8M · 3.7M shares | 3.7M | +1.9% |
| 3 | RTW INVESTMENTS, LP | $211.3M · 3.4M shares | 3.4M | +0.3% |
| 4 | Jupiter Topco LLC | $176.8M · 2.8M shares | 2.8M | — |
| 5 | Paradigm Biocapital Advisors LP | $174.7M · 2.8M shares | 2.8M | +8.3% |
| 6 | MORGAN STANLEY | $115M · 1.8M shares | 1.8M | -6% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | $112.9M · 1.8M shares | 1.8M | +1.8% |
| 8 | JENNISON ASSOCIATES LLC | $104.7M · 1.7M shares | 1.7M | -2.8% |
| 9 | TANG CAPITAL MANAGEMENT LLC | $98.7M · 1.6M shares | 1.6M | +31.9% |
| 10 | MILLENNIUM MANAGEMENT LLC | $89.8M · 1.4M shares | 1.4M | +152.8% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of TARS file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Nov 5, 2026 | FMR LLC13G · passive | 6.4% |
| Aug 13, 2026 | JANUS HENDERSON GROUP PLC13G · passive · amended | 6.5% |
| May 15, 2026 | Deep Track Capital, LP13G · passive · amended | 8.46% |
| May 8, 2026 | PRUDENTIAL FINANCIAL INC13G · passive · amended | 4.3%under 5% |
| May 6, 2026 | JENNISON ASSOCIATES LLC13G · passive · amended | 4%under 5% |
| Mar 27, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Get the Full Analysis for TARS
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.